

Shu G Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1043423/publications.pdf>

Version: 2024-02-01

89

papers

8,734

citations

53794

45

h-index

58581

82

g-index

92

all docs

92

docs citations

92

times ranked

6752

citing authors

#	ARTICLE	IF	CITATIONS
1	Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. <i>Alzheimer's and Dementia</i> , 2022, 18, 1248-1259.	0.8	7
2	Skin α -Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. <i>JAMA Neurology</i> , 2021, 78, 30.	9.0	125
3	Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson's disease and dementia with Lewy bodies. <i>Acta Neuropathologica Communications</i> , 2021, 9, 62.	5.2	79
4	Gut-microbiota-microglia-brain interactions in Alzheimer's disease: knowledge-based, multi-dimensional characterization. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 177.	6.2	15
5	Diagnostic value of skin RT-QuIC in Parkinson's disease: a two-laboratory study. <i>Npj Parkinson's Disease</i> , 2021, 7, 99.	5.3	41
6	Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. <i>Cell Research</i> , 2019, 29, 313-329.	12.0	42
7	Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 157-165.	2.6	29
8	Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls. <i>Journal of the Neurological Sciences</i> , 2018, 388, 203-207.	0.6	13
9	Novel strain properties distinguishing sporadic prion diseases sharing prion protein genotype and prion type. <i>Scientific Reports</i> , 2017, 7, 38280.	3.3	18
10	Exposure to the Functional Bacterial Amyloid Protein Curli Enhances Alpha-Synuclein Aggregation in Aged Fischer 344 Rats and <i>Caenorhabditis elegans</i> . <i>Scientific Reports</i> , 2016, 6, 34477.	3.3	319
11	Regulation of DJ-1 by Glutaredoxin 1 in Vivo: Implications for Parkinson's Disease. <i>Biochemistry</i> , 2016, 55, 4519-4532.	2.5	29
12	Prion protein functions as a ferriredoxase partner for ZIP14 and DMT1. <i>Free Radical Biology and Medicine</i> , 2015, 84, 322-330.	2.9	67
13	Glutaredoxin deficiency exacerbates neurodegeneration in <i>C. elegans</i> models of Parkinson's disease. <i>Human Molecular Genetics</i> , 2015, 24, 1322-1335.	2.9	38
14	The roles of redox enzymes in Parkinson's disease: Focus on glutaredoxin. <i>Therapeutic Targets for Neurological Diseases</i> , 2015, 2, .	2.2	9
15	pH-dependent kinetics of copper ions binding to amyloid- β peptide. <i>Journal of Inorganic Biochemistry</i> , 2013, 119, 21-27.	3.5	17
16	Kinase inhibitors arrest neurodegeneration in cell and <i>C. elegans</i> models of LRRK2 toxicity. <i>Human Molecular Genetics</i> , 2013, 22, 328-344.	2.9	70
17	LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. <i>Human Molecular Genetics</i> , 2012, 21, 1931-1944.	2.9	356
18	LRRK2 Directly Interacts with DLP1 to Regulate Mitochondrial Dynamics and Function. <i>Microscopy and Microanalysis</i> , 2012, 18, 196-197.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Assessing Prion Infectivity of Human Urine in Sporadic Creutzfeldt-Jakob Disease. <i>Emerging Infectious Diseases</i> , 2012, 18, 21-28.	4.3	22
20	CD3 in Lewy pathology: does the abnormal recall of neurodevelopmental processes underlie Parkinson's disease. <i>Journal of Neural Transmission</i> , 2011, 118, 23-26.	2.8	13
21	Selection and characterization of DNA aptamers against PrP ^{Sc} . <i>Experimental Biology and Medicine</i> , 2011, 236, 466-476.	2.4	20
22	LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a <i>Caenorhabditis elegans</i> model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2010, 40, 73-81.	4.4	128
23	Divalent metal transporter, iron, and Parkinson's disease: A pathological relationship. <i>Cell Research</i> , 2010, 20, 397-399.	12.0	13
24	Paradoxical Role of Prion Protein Aggregates in Redox-Iron Induced Toxicity. <i>PLoS ONE</i> , 2010, 5, e11420.	2.5	18
25	Characterization of the Prion Protein in Human Urine. <i>Journal of Biological Chemistry</i> , 2010, 285, 30489-30495.	3.4	14
26	Penicillin Sulfone Inhibitors of Class D β -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1414-1424.	3.2	42
27	Cryptic Peptides of the Kringle Domains Preferentially Bind to Disease-Associated Prion Protein. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 421-431.	2.6	8
28	Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 320-333.	3.6	105
29	Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease. <i>Journal of Neuroscience Research</i> , 2009, 87, 1283-1295.	2.9	109
30	Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2009, 4, 32.	10.8	34
31	The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. <i>Journal of Neuroscience Research</i> , 2008, 86, 1711-1720.	2.9	155
32	Leucine-Rich Repeat Kinase 2 Colocalizes with α -Synuclein in Parkinson's Disease, but Not Tau-Containing Deposits in Tauopathies. <i>Neurodegenerative Diseases</i> , 2008, 5, 222-224.	1.4	29
33	FadA from <i>Fusobacterium nucleatum</i> Utilizes both Secreted and Nonsecreted Forms for Functional Oligomerization for Attachment and Invasion of Host Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 25000-25009.	3.4	139
34	Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 6800-6805.	7.1	35
35	The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. <i>Experimental Cell Research</i> , 2007, 313, 3658-3670.	2.6	192
36	Leucine-rich repeat kinase 2: Relevance to Parkinson's disease. <i>International Journal of Biochemistry and Cell Biology</i> , 2006, 38, 1469-1475.	2.8	44

#	ARTICLE	IF	CITATIONS
37	Advances in Prion Disease Surveillance. <i>Advances in Clinical Chemistry</i> , 2006, 41, 263-292.	3.7	0
38	Gerstmann-Str�ussler-Scheinker. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 642-651.	1.7	33
39	DNA Aptamers That Bind to PrP ^C and Not Prp ^{Sc} Show Sequence and Structure Specificity. <i>Experimental Biology and Medicine</i> , 2006, 231, 204-214.	2.4	89
40	LRRK2 in Parkinson's disease and dementia with Lewy bodies. <i>Molecular Neurodegeneration</i> , 2006, 1, 17.	10.8	40
41	Overexpression of GRK2 in alzheimer disease and in a chronic hypoperfusion rat model is an early marker of brain mitochondrial lesions. <i>Neurotoxicity Research</i> , 2006, 10, 43-56.	2.7	76
42	LRRK2 protein is a component of lewy bodies. <i>Annals of Neurology</i> , 2006, 60, 617-618.	5.3	57
43	Fusion of Doppel to Octapeptide Repeat and N�Terminal Half of Hydrophobic Region of Prion Protein Confers Resistance to Serum Deprivation. <i>Microbiology and Immunology</i> , 2006, 50, 203-209.	1.4	20
44	Chronic Wasting Disease of Elk and Deer and Creutzfeldt-Jakob Disease. <i>Journal of Biological Chemistry</i> , 2006, 281, 4199-4206.	3.4	37
45	Sensitive Detection of Prion Protein in Human Urine. <i>Experimental Biology and Medicine</i> , 2005, 230, 343-349.	2.4	13
46	Chronic Wasting Disease of Elk: Transmissibility to Humans Examined by Transgenic Mouse Models. <i>Journal of Neuroscience</i> , 2005, 25, 7944-7949.	3.6	235
47	Creutzfeldt-Jakob Disease (CJD) with a Mutation at Codon 148 of Prion Protein Gene. <i>American Journal of Pathology</i> , 2005, 167, 1729-1738.	3.8	34
48	Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2005, 229-230, 285-292.	0.6	55
49	Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. <i>Neurology</i> , 2004, 63, 436-442.	1.1	119
50	Protease-Resistant Human Prion Protein and Ferritin Are Cotransported across Caco-2 Epithelial Cells: Implications for Species Barrier in Prion Uptake from the Intestine. <i>Journal of Neuroscience</i> , 2004, 24, 11280-11290.	3.6	96
51	Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease?. <i>Neurological Research</i> , 2004, 26, 547-553.	1.3	28
52	Antibody to DNA detects scrapie but not normal prion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 1380-1385.	7.1	103
53	Copper Mediates Dityrosine Cross-Linking of Alzheimer's Amyloid-��. <i>Biochemistry</i> , 2004, 43, 560-568.	2.5	362
54	Characterization of Prion Proteins. , 2003, 217, 305-314.		7

#	ARTICLE	IF	CITATIONS
55	Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clinics in Laboratory Medicine, 2003, 23, 43-64.	1.4	57
56	Sporadic and familial CJD: classification and characterisation. British Medical Bulletin, 2003, 66, 213-239.	6.9	449
57	Identification of Novel Proteinase K-resistant C-terminal Fragments of PrP in Creutzfeldt-Jakob Disease. Journal of Biological Chemistry, 2003, 278, 40429-40436.	3.4	129
58	Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease. Neurology, 2002, 58, 362-367.	1.1	50
59	Alteration of Substrate Selectivity through Mutation of Two Arginine Residues in the Binding Site of Amadoriase II from Aspergillus sp.. Biochemistry, 2002, 41, 4453-4458.	2.5	22
60	A Journey through the Species Barrier. Neuron, 2002, 34, 854-856.	8.1	16
61	Induction of HO-1 and NOS in Doppel-Expressing Mice Devoid of PrP: Implications for Doppel Function. Molecular and Cellular Neurosciences, 2001, 17, 768-775.	2.2	62
62	Mechanisms of phenotypic heterogeneity in prion, Alzheimer and other conformational diseases. Journal of Alzheimer's Disease, 2001, 3, 87-95.	2.6	6
63	Molecular profiling of paired helical filaments. Journal of Alzheimer's Disease, 2001, 3, 467-469.	2.6	0
64	Aberrant metal binding by prion protein in human prion disease. Journal of Neurochemistry, 2001, 78, 1400-1408.	3.9	178
65	Absence of protease-resistant prion protein in the cerebrospinal fluid of Creutzfeldt-Jakob disease. Journal of Pathology, 2001, 194, 9-14.	4.5	36
66	Novel Differences between Two Human Prion Strains Revealed by Two-dimensional Gel Electrophoresis. Journal of Biological Chemistry, 2001, 276, 37284-37288.	3.4	53
67	Genetic influence on the structural variations of the abnormal prion protein. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 10168-10172.	7.1	285
68	Aggregation and Fibrillization of the Recombinant Human Prion Protein huPrP90~231. Biochemistry, 2000, 39, 424-431.	2.5	216
69	Expression and Structural Characterization of the Recombinant Human Doppel Protein,. Biochemistry, 2000, 39, 13575-13583.	2.5	38
70	Cloning of Amadoriase I Isoenzyme from Aspergillus sp.: Evidence of FAD Covalently Linked to Cys342. Biochemistry, 2000, 39, 1515-1521.	2.5	45
71	PrPSc typing by N-terminal sequencing and mass spectrometry. , 2000, , 209-216.		7
72	Tau gene mutation in familial progressive subcortical gliosis. Nature Medicine, 1999, 5, 454-457.	30.7	189

#	ARTICLE	IF	CITATIONS
73	Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15598-15602.	7.1	90
74	Different patterns of truncated prion protein fragments correlate with distinct phenotypes in P102L Gerstmann-Straussler-Scheinker disease. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8322-8327.	7.1	206
75	Molecular Pathology of Fatal Familial Insomnia. Brain Pathology, 1998, 8, 539-548.	4.1	98
76	Mechanisms of Phenotypic Heterogeneity in Human Prion Diseases. , 1998, , 37-41.		0
77	Prion Protein Aggregation Reverted by Low Temperature in Transfected Cells Carrying a Prion Protein Gene Mutation. Journal of Biological Chemistry, 1997, 272, 28461-28470.	3.4	86
78	Allelic origin of the abnormal prion protein isoform in familial prion diseases. Nature Medicine, 1997, 3, 1009-1015.	30.7	88
79	Typing prion isoforms. Nature, 1997, 386, 232-233.	27.8	268
80	Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature, 1997, 388, 285-288.	27.8	259
81	Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Annals of Neurology, 1996, 39, 767-778.	5.3	819
82	Fatal Familial Insomnia and Familial Creutzfeldt-Jakob Disease: Clinical, Pathological and Molecular Features. Brain Pathology, 1995, 5, 43-51.	4.1	192
83	Regional distribution of protease-resistant prion protein in fatal familial insomnia. Annals of Neurology, 1995, 38, 21-29.	5.3	165
84	Truncated Forms of the Human Prion Protein in Normal Brain and in Prion Diseases. Journal of Biological Chemistry, 1995, 270, 19173-19180.	3.4	455
85	Synergistic activation by cis-fatty acid and diacylglycerol of protein kinase C and protein phosphorylation in hippocampal slices. Neuroscience, 1995, 68, 1017-1026.	2.3	3
86	PROTEASE-RESISTANT PRION PROTEIN IN SPORADIC CREUTZFELDT-JAKOB DISEASE (CJD). Journal of Neuropathology and Experimental Neurology, 1995, 54, 416.	1.7	3
87	Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2839-2842.	7.1	308
88	Inhibition of brain protein kinase C subtypes by lead. Journal of Pharmacology and Experimental Therapeutics, 1993, 264, 757-61.	2.5	53
89	The Roles of Redox Enzymes in Parkinson's Disease: Focus on Glutaredoxin. Therapeutic Targets for Neurological Diseases, 0, , .	2.2	5